Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Sinotau and Navidea Sign MOU for Beta-Amyloid Imaging Agent

publication date: Oct 30, 2017

Beijing's Sinotau Pharma signed a non-binding MOU with Navidea Biopharma to transfer rights for Navidea's beta-amyloid imaging agent to Cerveau Technologies. Cerveau is a Boston joint venture owned by Sinotau and Canada's Enigma Biomedical. Currently, Sinotau is suing Navidea. It charges Navidea did not transfer the global rights for the beta-amyloid imaging agent, NAV4694, to Sinotau as previously agreed. In 2014, Navidea in-licensed rights to NAV4694 from AstraZeneca, but later decided to emphasize other projects. More details....

Stock Symbols: (NYSE: NAVB) (NYSE: AZN)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Beijing and Digital
September 13-16, 2022
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
July 27-31, 2022